Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modificationsin the LUMINOSITY trial

Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: 1e39210b94aa6002ce2b191f1696071508ad7098
First added on: May 16, 2026